Even Five Years Postapproval, Many Drug Studies Remain Nonpublic
FRIDAY, Sept. 1, 2023 (HealthDay News) -- Only a fraction of evidence from completed studies is available publicly before drugs receive U.S. Food and Drug Administration approval, according to a study published in the August issue of Health Affairs Scholar.
Robert M. Kaplan, Ph.D., from Stanford University School of Medicine in California, and colleagues reviewed availability of results prior to and during the five years following each of the 46 novel drugs approved by the FDA in 2017.
The researchers found that the 46 drugs approved in 2017 were evaluated in 1,149 studies (range, two to 165 studies; mean, 24.98). Before approval, an average of 9.22 studies were started and 5.82 studies were completed. For 19 of the 46 approvals, a single trial justified approval. An average of 1.42 studies had results publicly posted prior to FDA approval. For nine of the approved drugs, no results were publicly reported before approval.
“We’re not saying that cancer drugs need a lot more studies; just that they should show all the results or trials that are completed,” coauthor Veronica Irvin, Ph.D., M.P.H., from Oregon State University in Corvallis, said in a statement. “It doesn’t mean they wouldn’t get approved, but it means we’d have a more complete picture.”
Related Posts
Braces for Adults
Am I too old for braces?Although teeth can be moved more easily while the jaw is...
Why Your Family History Is So Important to Your Doctor
SATURDAY, June 24, 2023 (HealthDay News) -- Your family medical history may...
Un estudio rastrea el curso natural de la infección y la transmisión de la COVID en pacientes individuales
MARTES, 3 de mayo de 2022 (HealthDay News) -- Los llamados "superpropagadores"...
Los pobres serán los más afectados por un mundo más caliente
MARTES, 15 de febrero de 2022 (HealthDay News) -- Un nuevo estudio muestra que...